🧬 Quitting Physics to Treat Biology Like an Engineering Problem | Richard Yu (Part 1/4)
Episode
38 min
Read time
2 min
Topics
Career Growth, Productivity, Relationships
AI-Generated Summary
Key Takeaways
- ✓Interdisciplinary entry strategy: Switching from physics to biophysics at Berkeley reframed biology from an observational science into an engineering discipline — a mental model Yu applies directly at Abalone Bio today. Founders with physics or engineering backgrounds should actively seek biology problems where first-principles thinking creates structural advantages over purely observational researchers.
- ✓Mentor selection over prestige: Yu chose his Yale postdoc advisor Axel Brünger and later Roger Brent at MSI based on intellectual alignment and applied focus, not name recognition. Early-career researchers benefit more from mentors building genuinely new frameworks — Brünger was simultaneously writing code and pipetting at midnight — than from attaching to established academic brands.
- ✓Cofounder compatibility signal: Yu identifies a specific early signal for cofounder fit with Gustavo Pesce: independently discovering they had both programmed identical text-based Space Invaders games on Apple II computers as children. Shared cognitive instincts and problem-solving defaults — not just complementary skills — predict durable cofounder relationships under startup pressure.
- ✓Radical honesty as leadership tool: Yu's cofounder modeled direct feedback by publicly telling Yu his conference talk was poor immediately after others offered false praise. Founders should build cultures where honest critique is delivered promptly and specifically — naming what failed and why — rather than allowing politeness to mask performance problems that compound over time.
- ✓Computational-experimental fluency gap: Yu observes that researchers equally comfortable with wet lab work and quantitative data analysis remain surprisingly rare even in 2024. Biotech founders who deliberately develop both skill sets — as Yu did from Berkeley through Yale structural biology — gain durable advantages in designing experiments and interpreting biological data at the systems level.
What It Covers
Richard Yu, cofounder and CEO of Abalone Bio, traces his path from physics undergraduate at UC Berkeley in 1989 through structural biology at Yale and systems biology at the Molecular Sciences Institute, revealing how immigrant upbringing, interdisciplinary training, and serial exposure to entrepreneurial culture shaped his approach to biotech founding.
Key Questions Answered
- •Interdisciplinary entry strategy: Switching from physics to biophysics at Berkeley reframed biology from an observational science into an engineering discipline — a mental model Yu applies directly at Abalone Bio today. Founders with physics or engineering backgrounds should actively seek biology problems where first-principles thinking creates structural advantages over purely observational researchers.
- •Mentor selection over prestige: Yu chose his Yale postdoc advisor Axel Brünger and later Roger Brent at MSI based on intellectual alignment and applied focus, not name recognition. Early-career researchers benefit more from mentors building genuinely new frameworks — Brünger was simultaneously writing code and pipetting at midnight — than from attaching to established academic brands.
- •Cofounder compatibility signal: Yu identifies a specific early signal for cofounder fit with Gustavo Pesce: independently discovering they had both programmed identical text-based Space Invaders games on Apple II computers as children. Shared cognitive instincts and problem-solving defaults — not just complementary skills — predict durable cofounder relationships under startup pressure.
- •Radical honesty as leadership tool: Yu's cofounder modeled direct feedback by publicly telling Yu his conference talk was poor immediately after others offered false praise. Founders should build cultures where honest critique is delivered promptly and specifically — naming what failed and why — rather than allowing politeness to mask performance problems that compound over time.
- •Computational-experimental fluency gap: Yu observes that researchers equally comfortable with wet lab work and quantitative data analysis remain surprisingly rare even in 2024. Biotech founders who deliberately develop both skill sets — as Yu did from Berkeley through Yale structural biology — gain durable advantages in designing experiments and interpreting biological data at the systems level.
Notable Moment
Yu describes watching Berkeley classmates join Netscape and Yahoo in 1993 while he earned $14,000 annually on an NIH grant pursuing structural biology on the East Coast — a parallel-path moment he still reflects on, though he credits that exact detour for making Abalone Bio possible.
You just read a 3-minute summary of a 35-minute episode.
Get The Biotech Startups Podcast summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Biotech Startups Podcast
🧬 From Games to Cancer Research: Why Drug Discovery Is an Economics Problem | Javier Tordable (3/4)
Jul 27 · 22 min
20VC (20 Minute VC)
20VC: $5BN in Revenue, 7 to 7,000 Employees in 9 Months, 206,000 Tests in a Single Day: The Craziest Story in Startups: Curative with Fred Turner
Jul 18
More from The Biotech Startups Podcast
🧬 16 Years at Google Taught Me How to Scale From 1 to 150 People | Javier Tordable (2/4)
Jul 23 · 28 min
The Long Run with Luke Timmerman
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Jun 30
More from The Biotech Startups Podcast
We summarize every new episode. Want them in your inbox?
🧬 From Games to Cancer Research: Why Drug Discovery Is an Economics Problem | Javier Tordable (3/4)
🧬 16 Years at Google Taught Me How to Scale From 1 to 150 People | Javier Tordable (2/4)
🧬 Video Games & a Whim Led Me to Microsoft | Javier Tordable (1/4)
🧬 Crossover Investing, Gene Therapy & LP Trust | Stephanie Sirota Rerelease (3/3)
🧬 Cycles, Conviction & Royalty Capital in Biotech Investing | Stephanie Sirota Rerelease (2/3)
Similar Episodes
Related episodes from other podcasts
20VC (20 Minute VC)
Jul 18
20VC: $5BN in Revenue, 7 to 7,000 Employees in 9 Months, 206,000 Tests in a Single Day: The Craziest Story in Startups: Curative with Fred Turner
The Long Run with Luke Timmerman
Jun 30
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
How I Built This
May 18
NVIDIA: Jensen Huang. From near collapse to becoming the world’s biggest company
Invest Like the Best with Patrick O'Shaughnessy
May 5
Brian Chesky - AI Founder Mode - [Invest Like the Best, EP.470]
Design Matters
Jan 26
Brian Chesky
Explore Related Topics
This podcast is featured in Best Science Podcasts (2026) — ranked and reviewed with AI summaries.
You're clearly into The Biotech Startups Podcast.
Every Monday, we deliver AI summaries of the latest episodes from The Biotech Startups Podcast and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime